Galphimia glauca for Depression
There is no human trial evidence that Galphimia glauca treats depression, and the limited animal data do not support an antidepressant effect. On current evidence it cannot be recommended for depression.
Why this grade7-layer evidence engine
This claim is graded Unverified (insufficient evidence) because no controlled human trials have tested Galphimia glauca for depression at all. The plant's genuine clinical research is for anxiety (generalized anxiety disorder), which is a distinct condition and cannot be borrowed to support an antidepressant claim. With only animal-level data available, the evidence simply does not reach the bar for a verdict.
The two depression-relevant preclinical studies are unconvincing. A 2006 mouse study (PMID 16360929) found that despite anxiety-reducing effects, the standardized extract failed to change immobility in the forced swimming test, the standard antidepressant screen, a negative result. A 2016 mouse study (PMID 27695258) reported dose-dependent CNS sedation and muscle relaxation; this is sedative 'depressant' activity, not antidepressant action, and does not support efficacy for depression.
No major authority has taken a position. The FDA, EFSA, UK NHS, WHO, NIH Office of Dietary Supplements, Mayo Clinic, Cleveland Clinic, Harvard Health, and the American Psychiatric Association all make no mention of Galphimia glauca for depression. This reflects an absence of evaluation rather than a positive endorsement, so it remains untested for this use.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.44
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 僅有 E10 級證據 (cohort/animal/mechanism)，不足以下結論
- tier_strict_requirement_check — C 級條件未達 (需 E1-E8；實際 E10 僅機轉)
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status